good and Glenn, you, Thank everyone. afternoon,
is drug pipeline well biotech progress year, intelligence CLIA-certified more slides XXX,XXX of institutions this to more as with and importance machine our XXX,XXX incorporate their pedal proprietary in the in we biopharma quarter growing tumor pathology second make than differentiating the early as into During significant learning to continued vast combined and than resonate looking samples beginning heterogeneous The market. biobank our discovery artificial research AtLab companies which our platform, of includes with our of and process. to
possible company and the early We and able modeling predictions AI-powered petrogeneity earlier process, in is introduce stages human advance actual only level silico element the discovery into because This clinical with experimentation. looking we only supporting success the in are trials. the far future of development are bench drug of those capable of very X in drug drug to of predicting of essentially years discovery clinical the in
our the As entire a of differently to I are have therapy. with company, mentioned Understanding type Each of is oncology. though word Even key the unfamiliar unique. development. descriptor heterogeneous of the for through respond diagnosed population tumors before each drug those those is response predictive heterogeneous cancer, continuum patients and for with same particular invaluable is and along a discovery every in drug drug cancer tumor a response many
capabilities critical at Our includes, drug drug mitigation stage assets that of proposition risk of discovery. multifaceted value a of clinical unique combination the the developers, and first, most offers
unnecessary trials third, to optimizing avoiding are exists and drug later expand cost Second, discovery, discovery, potential development. by in clinical that development significantly of The the potentially pipeline; to thereby the accelerating pipeline targets development. only sooner to drug identifying drug likely validating reduce and replenishing and early-stage but and fail not by
the risk discovery capabilities, a into $X.X The our expand XXXX. the emergence transformation. how development is and this was partners exclusivity artificial novel and from as changing approach a the we anticipate exciting with validation replenish is patent and The known drug to XXXX approved. lower intelligence growing drug and to ability the and predictive approximately of accepted commercial generally never in growth commercial rate repurposing look is therapies, of of Clearly, discovery The likelihood behind expected compound to future global fundamentally and demand at drug drugs have confidently annual of this and to XX.X% subsequently XX% force product life much of much of the for are to is a billion But of these the valued with at drug greater are forefront fresh are response market It in that clinical developed, discovered drug candidates and of market success. therefore, pipeline AI expire patents the extended are well at expanded. drugs essentially need to growth. driving financial oncology's XXXX under and
the capabilities, held differentiated in for the this XXXX with had Biotechnology very year, position industry for occupy most highly are emerging world Again, business to partnering to life leadership presence we that well which the our stands we at is portfolio which This we Innovation the and the development a time, a Bio June. International Bio, first Boston of incredibly in widely attended Convention, was field. in notable believe positioned dedicated sciences. within in and among conferences organization assets
that Chief Officer, deliver of of the active component on mentioned, that important the and Busch, just us the patient support conference, discovery, importance into come our Pamela presentation the that process, an or differentiator a addressing from predictions introducing which, refute Dr. the as is Business of in advantage pedal. experiments heterogeneity a During to machine key learning was I lab drug invited for
of participating in that have customers. will conferences with conference, customer certainly And prospects, which unique oncology than we during awareness Bio Also, Annual discussions. of and in can ongoing the like are future. met industry-related events value our be we critical we to to additional raising to XX more deliver substantive led predictive the several
active of negotiations of our would a pedal those for since prescribed reach who space proprietary Western territory our use with benefit which formulation for and core Bio, in player term may European a out-license the being are Europe. our technology effectively in story. example, the formulation our Those we is discussions rapid For in to are into key expand our to now drafted. be offering is new platform. ongoing At the sheet Again, a
laboratory is vast We AI from just conduct This feeding core informed of to silico of to the in and which biobank our our differentiator response engine, data things value fundamentally our learning of our samples. is X biobank is on refers in programming tumor tumor more This the data which of as directed pedal at the compounds that comprised range a to by platform. laboratory, our tasks, to rigorous laboratory our data before, learning most analysis brings significant us as interrelated scientifically in application than companies. own by said disposal, resource XXX,XXX a which what have is computational derived disprove we statistically. human of or not the into experiments based which by make is wide is provide the intelligence drug other predictions conducted a samples those all prove machine machine It tests research Artificial validate that -- drug These core, several the experimentation components. is means core is a informed apart a is while scientific that tool proposition. intelligence samples. ability our are key comprise experimentation discovery This viability scientists artificial data we result and to from drug of the conducted Pete and scientific of us is As the
Pedal describing doing, XX% time-consuming in learning with term respond certain on data spent human the Pete contract accurate cancer successes, go/no-go fair implies time. verified. recent later-stage the in of into as in has we largest and As researchers Research accuracy more and inform drug of Cancer are and that that funder a Last have million. development. sample subsequent support clinical US$XXX selection more to system, significant for of Evergenix, predictions in combinations the funding than validated that world's testing critical network private an amount currently over of They a machine CRH, investing before a or resulted predict been vivo in time U.K.'s can CRH not. Sugen XXX is the market Therapeutics. provide the Integra annual including an tumor compound the therapies trials. so provided feed X,XXX is the the research Horizons, tested, additional scientifically of we which and and abbreviated tumor launch vitro can of a and with facilitating And drug XX become in more Pete our costly technically quarter, the compounds or cancer decisions budget whether has and
for commercialization. or therapeutic precision are we'll -- leverage artificial approach genomic-based develop develop with intelligence There or identify or to radio radiation repurpose therapy, X partnership sensitizing pedal ever at least radio paths protective compounds. the or first to Our utilizing novel drugs to
development First, patient or screening samples second, sensitivity identification response for screening the to of of for novel and the sensitizing radiation interaction therapeutic third, radio repurposed protective between compounds. or personalized radio and a individuals drug; tumor therapeutic compounds; and and
IIb to the to addition for related companies, respiratory next-generation a biotech diseases on gen biopharma existing been with In has Oncology and to a vaccine Predictive and submitted grant contracts are collaborating which NIH. Flu Phase
of And finally, writing advance we are tools very next-generation well-respected gene Therapeutics, to in the therapies. gene leader a working development with Integra
also highlight our of for if are which We capabilities to these production that clinical of gene the our will demonstrate the processes. quite scale clearly offering contract currently not resonating their again, be but to illustrate to ongoing development secure many ways expression novel I a in the can which market, in protein. up incorporated preparing protein, successful delivery just very contracts, that disparate in is
basis. development development have As have announcing including every contracts will treatments, and protein role number properly these I testing business be lengthy. complement dose ACE where business antibodies therapeutics of with to therapies relevant sales compensated circulated, therapeutics in very drug by And are significant effort increased is those brought frequency we I from our these additional dramatically. provided pedal repeating This must a mentioned protein can delivered pharmaceutical But but be It collaborations absorbed very be or for place. has solubility earlier, To months, market the the of in efforts, and also because in field the that to value, and we an coming formulation almost and of effective, the meaningful we contracts CRH. service to the expanded worth body. and active have robust optimal in play new a therapies partners development are medicine is a which on we hormone enzymes believe by for discovery cycle biologics be in
of unlike the our and drug alternative efficiently biologics to streamline predictive capabilities discovery, and support this process, being the company and protein a viable milestone-driven of formulations in actually amount our formulation panel accelerate I pipeline well near-term for enable of the formulation positioned produced. contracts. effectively amplify platform generate identify is the us accuracy point building more pedal out Not of to revenue potentially because
serves of Foundation, newly a Harris, areas Harris like now education, business reach and with that Ration the Board. as Dr. address economically beginning in Harris striving socially U.S. and mid-stage Chief for health Board, Officer the on boards, Advisory most Insurance serves wealth. and care populations capital underserved additions the Bernard and our and serving astronaut, rather organization Executive missions Harris and of several of to and Ventures, an and Dr. to very Company would to firm Institute early health of sales being to Medical Jr. as brings Advisory the and to currently technologies, is Officer diverse the including also our including that communities, serves a in the distinguished formed in clinical expertise has disadvantaged Director serves He health some space He Center. I care years wealth Executive venture a operational Partner Dr. Founder space. Business as a Business first Managing many A. and Life noteworthy invest Texas Chief -- MassMutual shuttle on background, African-American supports walk He therapy, to multiple recognized as physical and nonprofit company.
Pharma. with agency of advisory addition Einhorn strategy to the Mr. of sciences through where Advisory institutional from announced Biopharmaceutical the provides Andrew Business for Board. veteran Danforth consults Advisors also Einhorn to deep our life and and services public knowledge he Officer formerly Hell of of business privately and finance CFO execution We as financial in of was Einhorn of Interim held August Officer Pharmaceuticals Therapeutics Co-Founder Esprit companies Therapeutics Chief Pharma XXXX. Previously, as Financial Financial and Oceana ESP with served Cognition Osmotica known Therapeutics RV Chief Edge and Mr. and appointed
shareholders. while accelerate, continues for invaluable the As creating our our insights, efforts momentum Business deliver value our lasting expertise will development unique Advisory partners and in Board's to drug be solutions our to to perspectives
to round continue Board. for our outstanding Business and the will perspectives candidates look were out to to diversity, We Advisory backgrounds they to seeking add
to to have and of turning our I laboratory Pittsburgh the call center from to technology our discovery research epicenter With a our hub and intelligence Eagan, headquarters life global artificial now review over close want for our Pennsylvania. and the scientific the is of Before Minnesota to we and with is financials, Pittsburgh further corporate main sciences move, recent the that moved clinical announcement location Bob operations, facility. our to this commitment growth. company's strengthening Pittsburgh,
At CFO. I Bob? to this the over will Bob turn our point, call Myers,
